Explore

Trendline Trendline
Anixa Biosciences to Present at Biotech Resurgence Conference on Cancer Vaccines

Anixa Biosciences to Present at Biotech Resurgence Conference on Cancer Vaccines

Anixa Biosciences to Present at Biotech Resurgence Conference on Cancer Vaccines
Trendline Trendline
Stoke Therapeutics to Present at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Amylyx Pharmaceuticals to Present at Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Virtual Healthcare Conference
Trendline Trendline
Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference

Stoke Therapeutics to Present Zorevunersen at Needham Virtual Healthcare Conference
Trendline Trendline
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to Board Amid Dravet Syndrome Treatment Advances
Trendline Trendline
Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies

Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies

Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies
Trendline Trendline
Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage
Trendline Trendline
Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Trendline Trendline
Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio

Gilead Sciences Acquires Tubulis in $5 Billion Deal to Expand Oncology Portfolio
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition